Physician Perspectives 2017: Use of ustekinumab in IBD

Physician Perspectives 2017: Use of ustekinumab in IBD


This Physician Perspectives survey focuses on the use of ustekinumab in IBD.

UST appears to be the preferred non-TNF biologic for treatment of moderate-to-severe Crohn’s disease, most frequently prescribed after the failure of one or two anti-TNFs (most often IFX & ADA), and before VDZ.

73% of physicians reported having had high expectations of UST's efficacy, and 58% stated that these expectations had been met, while 12% stated that they had not been met.

Majority of physicians expected UST to be somewhat effective or effective to treat UC patients with left-sided UC, non-acute, steroid dependent UC, extensive UC, ulcerative proctitis, acute severe colitis, and to treat patients with a high BMI.

The report includes following topics -

  • Current clinical use of UST
  • UST safety & efficacy
  • UST patient monitoring
  • Treatment response to UST
  • UST treatment strategies
  • Future use in UC.
  • Sociable Pharma conducted an online survey in Q4 2017, with 100 specialist gastroenterologists
  • Physicians interviewed were from 5EU and US countries
  • This report contains the findings from the survey, together with analysis, as well as an overview of the methodology used, and responder demographics.
Reasons to buy
  • Qualitative insight from 100 high-prescribing specialists in IBD
  • Includes insight & recommendations from our disease-specific healthcare analysts
  • Utilizes independent expert viewpoints to validate the impact of emerging trends on management of IBD
  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Executive Summary
Survey Results

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook